We are excited to congratulate the Hong Kong Med-Tech Association (HKMTA) on their new name, reflecting a stronger focus on technology. Our President and Managing Director, Jennifer Che, along with Principal Pauli Wong, were thrilled to celebrate this significant milestone with the organization at the recent HKMHDIA Medical Fair Forum.

Pauli, the official IP Advisor to HKMTA, joined Jennifer, one of the keynote speakers at the event, who shared about the importance of a well-thought-out intellectual property strategy for healthcare inventions. Jennifer emphasized the challenges of protecting biomedical products that operate at the intersection of regulatory affairs, IP, trade secret, and data privacy, particularly in the complex, multijurisdictional landscape of the Greater Bay Area (GBA). The event fostered valuable discussions on navigating these complexities, reinforcing our commitment to helping innovators safeguard their groundbreaking ideas.

我們過去活動

Recommended Insights

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]

The Latest on Post-Filing Data in China’s Patent Law

2020年4月29日
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

2024年1月9日
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]
Top crossarrow-right